Environmental Effects Type 1 Diabetes Mellitus

What Was Tested

This registered not phased trial tested Insulin Lispro.

Type 1 Diabetes mellitus (T1D) is characterized by βcell destruction and a long life requirement of exogenous insulin.

The bolus basal insulin regimen is a widely accepted therapy concept to treat hyperglycaemia in patients with T1D.

This concept requires a very good knowledge of the individuals prandial and basal insulin requirements.

It had 1 arm (groups): Patients with Type 1 Diabetes (other).

The registry classes the interventions as drug.

More on the Plan

BACKGROUND Type 1 Diabetes mellitus (T1DM) is characterised by β-cell destruction and a lifelong requirement of exogenous insulin.

The basal-bolus insulin regimen is widely accepted therapy to treat hyperglycaemia in patients with T1DM.

This concept requires a very good knowledge of the individual's prandial and basal insulin requirements.

However, insulin requirement depends on insulin absorption from the injection site and the individual's insulin sensitivity that relies on a number of factors including body composition, inflammatory processes and environmental factors.

Who Took Part

The registry lists 10 actual participants took part.

It was open to men only aged from 18 years up to 55 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Diabetes mellitus type 1. Age between 18 and 55 years, both inclusive. Body mass index (BMI) between 18.0 and 28.0 kg/m2, both inclusive. Informed consent must be obtained for all volunteers in writing.

The full record lists 7 inclusion and 5 exclusion criteria; among the exclusions: known or suspected allergy to insulin; recurrent major hypoglycaemia or hypoglycaemic unawareness as judged by the investigator or hospitalization for diabetic ketoacidosis during the previous 6 months; treatment with any other investigational drug within 3 months prior to screening. participation in a clinical research trial in last 3 months.

How the Study Was Run

The set-up was single-group and open-label.

Everyone knew when Insulin Lispro was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2016-06 with completion listed for 2018-02-02.

It ran at 1 site in United Kingdom.

Its stated primary purpose is basic science.

What Was Measured

Researchers chose this as the main measure: Area under the glucose infusion rate curve from 0 hours until the end of clamp (time frame: 1 Year).

It also tracked 6 secondary outcomes, for example Area under the glucose infusion rate curve from 0 hours until 2 hours, Area under the glucose infusion rate curve from 0 hours until 4 hours, Area under the glucose infusion rate curve from 0 hours until 6 hours, Area under the glucose infusion rate curve from 4 hours until 6 hours, Maximum glucose infusion rate and Time to maximum glucose infusion rate curve.

What This Means in Plain Language

Put simply, this is a not phased trial of Insulin Lispro in 10 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Insulin Lispro compound page, all human trials.